These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30952723)

  • 1. Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.
    Mego M; Karaba M; Minarik G; Benca J; Silvia J; Sedlackova T; Manasova D; Kalavska K; Pindak D; Cristofanilli M; Reuben JM; Mardiak J
    Anticancer Res; 2019 Apr; 39(4):1829-1837. PubMed ID: 30952723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
    Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy.
    Mego M; Mani SA; Lee BN; Li C; Evans KW; Cohen EN; Gao H; Jackson SA; Giordano A; Hortobagyi GN; Cristofanilli M; Lucci A; Reuben JM
    Int J Cancer; 2012 Feb; 130(4):808-16. PubMed ID: 21387303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial‑mesenchymal transition was identified as a potential marker for breast cancer aggressiveness using reverse transcription‑quantitative polymerase chain reaction.
    Andergassen U; Schlenk K; Jeschke U; Sommer H; Kölbl A
    Mol Med Rep; 2018 Aug; 18(2):1733-1739. PubMed ID: 29845200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.
    Cierna Z; Mego M; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Cingelova S; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2014 Jun; 14():472. PubMed ID: 24972610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer.
    Mego M; Cholujova D; Minarik G; Sedlackova T; Gronesova P; Karaba M; Benca J; Cingelova S; Cierna Z; Manasova D; Pindak D; Sufliarsky J; Cristofanilli M; Reuben JM; Mardiak J
    BMC Cancer; 2016 Feb; 16():127. PubMed ID: 26896000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship Between Circulating Tumor Cells and Annexin A2 in Early Breast Cancer Patients.
    Bystricky B; Cierna Z; Sieberova G; Janega P; Karaba M; Minarik G; Benca J; Sedlackova T; Jurisova S; Gronesova P; Pindak D; Macuch J; Mardiak J; Mego M
    Anticancer Res; 2017 May; 37(5):2727-2734. PubMed ID: 28476852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
    Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
    Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of EMT Markers SLUG and TWIST in Breast Cancer.
    Grzegrzolka J; Biala M; Wojtyra P; Kobierzycki C; Olbromski M; Gomulkiewicz A; Piotrowska A; Rys J; Podhorska-Okolow M; Dziegiel P
    Anticancer Res; 2015 Jul; 35(7):3961-8. PubMed ID: 26124343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
    Kasimir-Bauer S; Hoffmann O; Wallwiener D; Kimmig R; Fehm T
    Breast Cancer Res; 2012 Jan; 14(1):R15. PubMed ID: 22264265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship Between Circulating Tumor Cells and Tissue Plasminogen Activator in Patients with Early Breast Cancer.
    Bystricky B; Jurisova S; Karaba M; Minarik G; Benca J; Sedlácková T; Tothova L; Vlkova B; Cierna Z; Janega P; Manasova D; Gronesova P; Pindak D; Mardiak J; Celec P; Mego M
    Anticancer Res; 2017 Apr; 37(4):1787-1791. PubMed ID: 28373442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
    Papadaki MA; Stoupis G; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
    Mol Cancer Ther; 2019 Feb; 18(2):437-447. PubMed ID: 30401696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
    Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion.
    Imani S; Wei C; Cheng J; Khan MA; Fu S; Yang L; Tania M; Zhang X; Xiao X; Zhang X; Fu J
    Oncotarget; 2017 Mar; 8(13):21362-21379. PubMed ID: 28423483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous Manifestations of Epithelial-Mesenchymal Plasticity of Circulating Tumor Cells in Breast Cancer Patients.
    Tashireva LA; Savelieva OE; Grigoryeva ES; Nikitin YV; Denisov EV; Vtorushin SV; Zavyalova MV; Cherdyntseva NV; Perelmuter VM
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.